The estimated Net Worth of Rodger Novak is at least $66.7 Millón dollars as of 30 June 2021. Rodger Novak owns over 25,000 units of CRISPR Therapeutics AG stock worth over $26,037,438 and over the last 8 years he sold CRSP stock worth over $39,968,624. In addition, he makes $645,572 as Chairman of the Board, President y Co-Founder at CRISPR Therapeutics AG.
Rodger has made over 30 trades of the CRISPR Therapeutics AG stock since 2017, according to the Form 4 filled with the SEC. Most recently he sold 25,000 units of CRSP stock worth $4,125,000 on 30 June 2021.
The largest trade he's ever made was exercising 100,000 units of CRISPR Therapeutics AG stock on 30 November 2020 worth over $1,422,000. On average, Rodger trades about 37,209 units every 46 days since 2016. As of 30 June 2021 he still owns at least 573,007 units of CRISPR Therapeutics AG stock.
You can see the complete history of Rodger Novak stock trades at the bottom of the page.
Dr. Rodger Novak M.D. serves as Chairman of the Board, President, Co-Founder of the Company. He has served as a director on our Board of Directors since inception, served as our Chief Executive Officer until December 1, 2017 and, since that date, has served as our President and since December 21, 2017 as our Chairman. Prior to joining our company, Dr. Novak served as Global Head Anti-infectives Research and Development at Sanofi, a pharmaceutical company. Prior to Sanofi, Dr. Novak co-founded Nabriva Therapeutics AG, a biopharmaceutical company, in January 2006, and served as its Chief Operating Officer from inception to May 2012. From March 2003 to January 2006, Dr. Novak served as the Deputy Head of the Antibiotic Research Institute at Sandoz GmbH. Dr. Novak was appointed as Professor for Microbiology at the Vienna Biocenter in March 2001. Dr. Novak received an M.D. from Philipps University of Marburg, Germany. He continued with post-doctoral work in New York City at The Rockefeller University, St. Jude Children’s Research Hospital and the Skirball Institute of Biomolecular Medicine at NYU Langone Medical Center. Dr. Novak has authored numerous publications, including articles in Nature, Nature Medicine and Molecular Cell and is a co-inventor of five patents. Novak’s experience as our Chief Executive Officer, as well as his experience in the biopharmaceutical industry, qualifies him to serve on our Board of Directors.
As the Chairman of the Board, President y Co-Founder of CRISPR Therapeutics AG, the total compensation of Rodger Novak at CRISPR Therapeutics AG is $645,572. There are 8 executives at CRISPR Therapeutics AG getting paid more, with Samarth Kulkarni having the highest compensation of $16,265,700.
Rodger Novak is 52, he's been the Chairman of the Board, President y Co-Founder of CRISPR Therapeutics AG since 2017. There are 7 older and 8 younger executives at CRISPR Therapeutics AG. The oldest executive at CRISPR Therapeutics AG is Katherine High, 68, who is the Independent Director.
Rodger's mailing address filed with the SEC is C/O CRISPR THERAPEUTICS, INC., 610 MAIN STREET, CAMBRIDGE, MA, 02139.
Over the last 8 years, insiders at CRISPR Therapeutics AG have traded over $284,003,967 worth of CRISPR Therapeutics AG stock and bought 3,347,446 units worth $53,410,590 . The most active insiders traders include Plc Gsk, Ali Behbahani y Corp /De/ Celgene. On average, CRISPR Therapeutics AG executives and independent directors trade stock every 13 days with the average trade being worth of $2,405,548. The most recent stock trade was executed by Julianne Bruno on 20 June 2024, trading 7,000 units of CRSP stock currently worth $318,080.
CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.
CRISPR Therapeutics AG executives and other stock owners filed with the SEC include: